J A RAFFERTY
Overview
Explore the profile of J A RAFFERTY including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Young L, PLATZER R, RAFFERTY J
J Lab Clin Med
. 2010 Mar;
32(5):489-501.
PMID: 20296442
No abstract available.
2.
Baum C, Fairbairn L, Hildinger M, Lashford L, Hegewisch-Becker S, RAFFERTY J
Expert Rev Mol Med
. 2004 Feb;
1999:1-28.
PMID: 14987353
The effectiveness of anti-cancer chemotherapy can be limited by acute suppression of the bone marrow (myelosuppression). There is also a risk of therapy-related secondary haematopoietic malignancy as well as acute...
3.
Turner S, Wijnhoven S, Tinwell H, Lashford L, RAFFERTY J, Ashby J, et al.
Mutat Res
. 2001 Aug;
493(1-2):139-47.
PMID: 11516723
The topoisomerase II inhibitor etoposide is used routinely to treat a variety of cancers in patients of all ages. As a result of its extensive use in the clinic and...
4.
Turner S, RAFFERTY J, Fairbairn L, Ashby J, Tinwell H, ECKERT H, et al.
Leukemia
. 2000 Oct;
14(10):1796-802.
PMID: 11021755
We have used the bone marrow micronucleus assay (BMMN) as a measure of clastogenicity, in response to etoposide exposure in murine bone marrow. Oral delivery of etoposide resulted in a...
5.
Fairbairn L, RAFFERTY J, Lashford L
Bone Marrow Transplant
. 2000 Aug;
25 Suppl 2:S110-3.
PMID: 10933202
Many of the problems with current anti-tumour therapies stem from a lack of specificity for tumour as opposed to normal tissues. To address the problem of collateral toxicity during anti-tumour...
6.
Thompson M, Baker T, RAFFERTY J, Margison G, Bibby M
J Reprod Fertil
. 2000 Jun;
119(2):339-46.
PMID: 10864847
The O(6)-alkylguanine-DNA alkyltransferase inactivator O(6)-benzylguanine was administered to BALB/c mice either alone or before exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea to study the role of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase in the...
7.
Bellantuono I, Lashford L, RAFFERTY J, Fairbairn L
Haematologica
. 2000 May;
85(5):451-7.
PMID: 10800158
Background And Objective: As a single gene defect in mature bone marrow cells, chronic granulomatous disease (X-CGD) represents a disorder which may be amenable to gene therapy by the transfer...
8.
Fairbairn L, Chinnasamy N, Lashford L, Chinnasamy D, RAFFERTY J
Cancer Gene Ther
. 2000 Apr;
7(2):233-9.
PMID: 10770631
Retroviral gene transfer was used to achieve expression in mouse bone marrow of a mutant form of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (hATPA/GA), which exhibits resistance to inactivation by...
9.
Rajaguru P, Fairbairn L, Ashby J, Willington M, Turner S, Woolford L, et al.
Mutat Res
. 1999 Sep;
444(1):175-80.
PMID: 10477352
The clastogenicity of the azo dye Direct Red 2 (DR2) has been investigated using the murine bone marrow micronucleus assay. A potent dose-dependent response was observed following oral gavage of...
10.
Jelinek J, RAFFERTY J, Cmejla R, Hildinger M, Chinnasamy D, Lashford L, et al.
Gene Ther
. 1999 Sep;
6(8):1489-93.
PMID: 10467374
Following transduction with a retrovirus (SF1MIH) expressing both the multidrug resistance 1 (MDR1) and O6-alkylguanine-DNA-alkyltransferase (ATase) proteins, human erythroleukaemic progenitor (K562) cells were isolated which were resistant to killing by...